NCT04585490 - Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 25, 2021

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2028

Conditions

Non Small Cell Lung CancerNSCLC, Stage IIINsclc

Interventions

DRUG

Durvalumab

Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)

DRUG

Carboplatin

Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle

DRUG

Pemetrexed

500mg/m2 on Day 1 of every 21-day cycle

DRUG

Paclitaxel

175mg/m2 on Day 1 of every 21-day cycle

DRUG

Cisplatin

Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin

DEVICE

AVENIO ctDNA Surveillance Kit

Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)

DRUG

Tremelimumab

not to exceed 75mg IV on Day 1 of every 21-day cycle

Trial Locations (1)

RECRUITING

Stanford University, Stanford